ADANIPORTS’ topline growth remains container-led (20%+ CAGR), with Vizhinjam and Mundra as key drivers; bottomline benefits from operating leverage but faces execution risks in logistics/international ports; margins hinge on coal mix optimization and NQXT contract renegotiations, targeting 56–58% EBITDA by FY29.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables:Vizhinjam on schedule, container growth at 20% CAGR, coal mix stabilizes at 20%.
Outcome:FY29 targets met (INR 65,500 crore revenue, INR 36,500 crore EBITDA). Mundra/CT5 drives 60% of container growth; logistics EBITDA margins expand to 25%. Net debt/EBITDA at 1.5x; shareholder returns via buybacks.
JSW Steel’s topline growth (10–15% CAGR) hinges on domestic demand (7–9%) and Odisha/Dolvi execution; bottomline leverage to capex timing and coking coal costs; margins (14–16%) depend on value-added mix expansion and CBAM mitigation, with structural support from raw material security and policy tailwinds.
1–2 minutes
3-Scenario Framework
📊 Base Case (60% Probability)
Key variables: BPSL closure by March 2026; BF-3 ramp-up on schedule (April 2026); 7–9% domestic demand growth. Outcome: Net debt/EBITDA normalizes to 2x by FY27 as BPSL cash (Rs.24,400 crore) funds capex. Odisha Phase-1 (5M tonnes) and Dolvi Phase-3 (5M tonnes) deliver 10M tonnes incremental capacity by FY28, supporting 15%+ EBITDA margins. CBAM impact limited to <5% of export volumes; Europe realisations adjust via price pass-through. Topline: 10–12% CAGR; bottomline: 15–18% EPS growth.
SBI outlook spans three scenarios: Base Case with stable NIM at 3.0% and ROE near 21%; Bear Case with margin compression to 2.8% amid NPL stress; Bull Case with NIM expansion above 3.1% and ROE exceeding 22%.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: (1) Corporate credit growth sustains at 13–15% with term loan mix improvement, (2) CASA ratio holds at 39–40%. Outcome: NIM stabilizes at 3.0%, credit costs at 0.30–0.35%, and fee income grows 15–20% YoY (CVE + mutual fund dividends). ROA 1.0–1.1%, ROE 20–21%. Trigger: Budgetary infrastructure spend and MSME “champion” initiatives drive RAM growth; YONO scales to 15 crore users.
Sun Pharma’s topline growth is milestone-dependent and exposed to US generics structural decline, while bottom-line resilience hinges on tax rate stabilization and R&D productivity; margins face near-term pressure from launch costs but could inflect in FY28 if innovative scales and OAI risks abate—model 31–33% EBITDA as the new range.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key variables: (1) OAI resolutions by late FY27, enabling 2–3 major ANDA launches; (2) Unloxcyt/LEQSELVI hit $200M run rate by FY28.
Outcome: Revenue grows 10–12% (ex-FX), with India/Semaglutide contributing 40% of incremental sales. EBITDA margins stabilize at 31–32%; EPS grows 6–8% on tax headwinds. Implication: In-line with consensus; 22–24x PE sustained.
L&T’s FY27 outcomes diverge across scenarios. Revenue growth spans 10–17%, with P&M margins between 7.5–9.0% and NWC/Revenue ranging 7–13%. EPS shifts from –8% to +20% YoY, shaped by Middle East orders, domestic capex trends, and new ventures in semiconductors and electrolyzers.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: (1) Middle East orders (TenneT packages 3–4) materialize in H1FY27; (2) Domestic private sector (real estate, thermal power) offsets public sector slowdown.
Outcome: Revenue growth at 14–15%; P&M margins recover to 8.3–8.5% in H2FY27. NWC/Revenue sustains at 9–10%. EPS grows 10–12% YoY, supported by Realty presales and data center ramp-up.
Cipla’s topline resilience hinges on US pipeline execution (respiratory/peptides) and India chronic therapy growth, while margins face near-term pressure from R&D lumpiness and Lanreotide disruption; FY27 EBITDA recovery to 21%+ requires flawless launch sequencing and cost normalization.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Lanreotide resumes in H1 FY27; two respiratory launches in H1 FY27 (one sole generic).
Generic Victoza and one peptide launch in FY27; Yurpeak traction sustains (~₹150 crore/month).
Result:US revenue stabilizes at $130–150M/quarter; EBITDA margin recovers to 20–21%; FY27 guidance maintained at 21%.
Bajaj Auto’s Base case sees contained inflation, steady domestic growth, and KTM recovery driving 15–18% revenue with 20–21% margins. Bear case risks commodity shocks, rupee appreciation, and demand slowdown, trimming margins to 19%. Bull case highlights premiumization, EV adoption, and KTM synergies, boosting revenue 20%+.